News Page
Published June 11, 2026
Regencell told investors it was developing traditional Chinese medicine treatments for ADHD and autism.
A tiny company with just 12 employees, no approved or salable products, no revenue, and a claimed TCM formula aimed at treating the fundamental cause of ADHD and autism.
Then, according to the complaint, the stock went wild.
According to the complaint, Regencell shares climbed from under $0.30 to about $78 by June 2025. A jump of more than 4,800%. Executives pointed instead to short sellers and third-party news and social media activity.
But investors allege the story was much worse.
The lawsuit claims Regencell failed to disclose that it was vulnerable to market manipulation, exposing investors to financial risk and the company to heightened government scrutiny.
Then, according to the complaint, the truth began to emerge in October 2025. Regencell disclosed in an SEC filing that the DOJ was investigating trading in its shares. The stock dropped about 19%.
Now, investors are learning more about the lawsuit.